Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
Maurie MarkmanUniversity of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: Both pre-clinical studies and phase 1–2 clinical trials have provided strong support for the potential role of regional drug delivery in the management of epithelial ovarian cancer, a disease process...
Saved in:
Main Author: | Maurie Markman (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2009-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
by: Sally Mullany, et al.
Published: (2020) -
Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy
by: Valerie A. Allen, et al.
Published: (2016) -
Role of hyperthermic intraperitoneal chemotherapy in combination with an intraperitoneal port system in the treatment of patients with advanced ovarian cancer
by: V. V. Saevets, et al.
Published: (2022) -
Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer
by: Wei-Chun Chen, et al.
Published: (2020) -
The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
by: Kate Glennon, et al.
Published: (2021)